Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts

  • Authors:
    • Shan Chen
    • Xiaoxia Liu
    • Wenfei Gong
    • Huan Yang
    • Daofei Luo
    • Xialin Zuo
    • Wenshi Li
    • Ping Wu
    • Li Liu
    • Qian Xu
    • Aimin Ji
  • View Affiliations

  • Published online on: October 19, 2012     https://doi.org/10.3892/or.2012.2097
  • Pages: 260-268
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

RNA targeting the murine vascular endothelial growth factor receptor 2 (VEGFR2) gene was designed and validated for efficient and robust silencing in vitro and was delivered by polyethylenimines (PEI) in vivo to investigate the antitumor effect on non-small cell lung cancer (NSCLC) xenografts. The following dosage regimens were tested for their tumor inhibitory effect in vivo: VEGFR2 siRNA, epidermal growth factor receptor (EGFR) siRNA, VEGFR2 siRNA+EGFR siRNA, cisplatin alone and VEGFR2 siRNA+ EGFR siRNA+cisplatin. Targeted silencing of both VEGFR2 and EGFR expression by siRNA, combined with low-dose cisplatin, was found to effectively inhibit tumor growth and extend the survival time of mice bearing the NSCLC xenografts. These results suggest that combination therapy using siRNAs and chemotherapy agents might offer a novel strategy for cancer treatment in the future.
View Figures
View References

Related Articles

Journal Cover

January 2013
Volume 29 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen S, Liu X, Gong W, Yang H, Luo D, Zuo X, Li W, Wu P, Liu L, Xu Q, Xu Q, et al: Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncol Rep 29: 260-268, 2013.
APA
Chen, S., Liu, X., Gong, W., Yang, H., Luo, D., Zuo, X. ... Ji, A. (2013). Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. Oncology Reports, 29, 260-268. https://doi.org/10.3892/or.2012.2097
MLA
Chen, S., Liu, X., Gong, W., Yang, H., Luo, D., Zuo, X., Li, W., Wu, P., Liu, L., Xu, Q., Ji, A."Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts". Oncology Reports 29.1 (2013): 260-268.
Chicago
Chen, S., Liu, X., Gong, W., Yang, H., Luo, D., Zuo, X., Li, W., Wu, P., Liu, L., Xu, Q., Ji, A."Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts". Oncology Reports 29, no. 1 (2013): 260-268. https://doi.org/10.3892/or.2012.2097